OBI Pharma Partners with TegMine Therapeutics on ADC Development Using GlycOBI® and TegMiner™ Technologies

TAIPEI, Taiwan I June 06, 2025 I OBI Pharma, Inc. (OBI) and TegMine Therapeutics, Inc. (TegMine) have announced a key collaboration aimed at advancing cancer therapy. OBI Pharma, a leading clinical-stage global oncology company, specializes in the development of innovative cancer treatments like antibody-drug conjugates (ADCs). TegMine Therapeutics, based in the United States, focuses on developing antibodies that target cancer-related glycans and glycoproteins. The partnership involves a Master Services Agreement (MSA) centered around ADC technology.

Under the agreement, OBI Pharma will provide TegMine access to its proprietary GlycOBI® ADC enabling technologies, which are enhanced by EndoSymeOBI® and HYPrOBI®. These technologies will be utilized by TegMine to identify promising ADC therapeutic candidates for potential progression into clinical development. Should these efforts yield an ADC product candidate, a formal licensing agreement would be established between OBI and TegMine.

Heidi Wang, Ph.D., CEO of OBI Pharma, expressed enthusiasm about the collaboration, emphasizing the strategic benefits of combining the strengths of both companies. She highlighted the opportunity to advance OBI's promising ADC products while utilizing innovative enabling technologies for strategic partnerships. Wang voiced her anticipation for working closely with TegMine to develop novel ADC candidates, addressing unmet medical needs in patient care.

Similarly, Jeff Bernstein, Ph.D., CEO of TegMine Therapeutics, spoke positively about the partnership, reflecting on the merging of two cutting-edge platforms. He noted that OBI’s ADC technology makes an ideal companion to TegMine’s initiatives to target cancer-specific glycans. Together, Bernstein believes the collaboration will enable the development of ADCs with unparalleled tumor specificity and therapeutic effectiveness.

GlycOBI® is a unique technology pioneered by OBI Pharma, characterized by a ‘Plug and Play’ format compatible with various antibodies, linkers, and payloads. Facilitated by OBI’s proprietary enzymatic and linker technologies, GlycOBI® produces site-specific, homogeneous ADCs through an efficient process under GMP conditions. This method avoids disrupting the structural integrity of the antibody, ensuring ADCs maintain similar biophysical attributes to the original antibody. Additionally, OBI's linker technology enhances the payload conjugation efficiency and reduces aggregation propensity, providing significant manufacturing advantages. GlycOBI® has surpassed traditional ADC limitations, demonstrating improved antitumor activity and stability in diverse in vivo studies.

Established in 2002, OBI Pharma is headquartered in Taiwan and is committed to developing novel cancer therapies for patients with significant unmet medical needs. OBI's innovative ADC pipeline includes first-generation TROP2 ADC, OBI-992, and second-generation variants like OBI-902 (TROP2), OBI-904 (Nectin-4), and Trastuzumab-ADC (HER2). Utilizing its unique technologies, OBI is also developing a next-generation ThiOBI® platform for cysteine-based conjugation. Furthermore, the company’s pipeline features the AKR1C3-targeted small-molecule prodrug OBI-3424, which releases a powerful DNA-alkylating antitumor agent in response to the aldo-keto reductase 1C3 enzyme prevalent in tumors.

Founded in 2017, TegMine Therapeutics is a biotechnology firm located in San Francisco, California. The company is dedicated to creating next-generation antibody-based therapies targeting cancer-associated glycans and glycoproteins. TegMine’s proprietary TegMiner™ platform facilitates the discovery and development of therapeutic antibodies targeting previously inaccessible glycan epitopes, revolutionizing oncology for patients with unmet needs.